A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.

The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.

Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.

Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.

Moderna has also canned projects targeting KRAS and Ox40L/IL-23/IL-36γ.

An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.

But the company hasn’t given details, and used a historical control rather than the study’s own control arm.

Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.

The group plays down upcoming interim analysis, but still hopes for accelerated approval.